This effect was enhanced when PBA was administrated in combination with the antioxidant AEOL 10150, suggesting that HDAC inhibitors and blocking oxidative stress agents may exert additive therapeutic effects in treating mutant SOD1-associated ALS and other neurodegenerative diseases [121]. This evidence concerns the gene HDAC9 and neurodegenerative disease.